Effect of Race on Cardiometabolic Responses to Once-weekly Exenatide: Insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Overview
Endocrinology
Authors
Affiliations
Background: To determine whether there were racial differences in short-term cardiometabolic responses to once-weekly exenatide (EQW) in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Methods: EXSCEL enrolled 14,752 patients with type 2 diabetes (hemoglobin A (HbA) 6.5-10.0% [48-86 mmol/mol]) with or without cardiovascular disease who were randomized double-blind to EQW or placebo. Background glucose-lowering/other cardiovascular therapies were unaltered for 6 months post-randomization unless clinically essential, facilitating comparison of EQW-associated effects in 14,665 evaluable participants self-identifying as White (n = 11,113), Asian (n = 1444), Black (n = 870), or Other Race (n = 1,238. Placebo-adjusted 6 month absolute changes in cardiometabolic variables were assessed using generalized linear models.
Results: Mean 6-month placebo-adjusted HbA reductions were similar in the four groups (range 0.54-0.67% [5.9 to 7.3 mmol/mol], P = 0.11 for race×treatment interaction), with no significant difference in Asians (reference) versus other groups after covariate adjustment (all P ≥ 0.10). Six-month placebo-adjusted mean changes in systolic (-1.8 to 0.0 mmHg) and diastolic (0.2 to 1.2 mmHg) blood pressure, serum LDL (- 0.06 to 0.02 mmol/L) and HDL (0.00 to 0.01 mmol/L) cholesterol, and serum triglycerides (-0.1 to 0.0 mmol/L) were similar in the racial groups (P ≥ 0.19 for race×treatment interaction and all P ≥ 0.13 for comparisons of Asians with other races). Resting pulse rate increased more in Asians (4 beats/min) than in other groups (≤ 3 beats/min, P = 0.016 for race×treatment interaction and all P ≤ 0.050 for comparisons of Asians with other races).
Conclusions: Short-term cardiometabolic responses to EQW were similar in the main racial groups in EXSCEL, apart from a greater pulse rate increase in Asians.
Trial Registration: https://clinicaltrials.gov NCT01144338.
Gao X, Li Q, Hao J, Sun K, Feng H, Guo K CNS Neurosci Ther. 2024; 30(7):e14835.
PMID: 39004783 PMC: 11246977. DOI: 10.1111/cns.14835.
Wang T, Ding J, Cheng X, Yang Q, Hu P Front Pharmacol. 2024; 15:1396656.
PMID: 38720777 PMC: 11076696. DOI: 10.3389/fphar.2024.1396656.
Gomes D, Presume J, de Araujo Goncalves P, Almeida M, Mendes M, Ferreira J Cardiovasc Drugs Ther. 2024; .
PMID: 38214869 DOI: 10.1007/s10557-024-07547-3.
Development of a core outcome set for cardiovascular diabetology: a methodological framework.
Jiao J, Chen L, Peng Y, Jia Q, He Y, Zhang Y Front Endocrinol (Lausanne). 2023; 14:1271891.
PMID: 38125792 PMC: 10731247. DOI: 10.3389/fendo.2023.1271891.